½ÃÀ庸°í¼­
»óǰÄÚµå
1701322

Á¾¾ç ÇÁ·ÎÆÄÀϸµ ½ÃÀå : ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ - ±â¹ýº°, ±â¼úº°, ¿ëµµº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2025-2030³â)

Tumor Profiling Market Size, Share & Trends Analysis Report By Technique (Genomics, Proteomics), By Technology, By Application (Personalized Cancer Medicine), By Region, And Segment Forecasts, 2025 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 100 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Á¾¾ç ÇÁ·ÎÆÄÀϸµ ½ÃÀåÀÇ ¼ºÀå ¹× µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°èÀÇ Á¾¾ç ÇÁ·ÎÆÄÀϸµ ½ÃÀå ±Ô¸ð´Â 2025-2030³â ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 10.4%·Î È®´ëµÉ Àü¸ÁÀ̸ç, 2030³â¿¡´Â 217¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾Ï °ËÃâ¿¡ À־ ¿À¹Í½º °úÇÐÀÇ ÀÀ¿ë ¿¬±¸ÀÇ °íÁ¶°¡ ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

»ý¸í °øÇÐÀÇ ±â¼úÀû Áøº¸´Â ´ë»ç¿Í À¯ÀüÀÚ ¹ßÇö¿¡ ´ëÇÑ ±íÀº ÀλçÀÌÆ®¸¦ Á¦°øÇß½À´Ï´Ù. À̰Ϳ¡ ÀÇÇØ ¸ÞŸº¸·Î¹Í½º³ª ÈļºÀ¯ÀüÇаú °°Àº ÷´Ü±â¼úÀÇ ¾Ï ½ºÅ©¸®´×À̳ª °ËÃâ¿¡ ´ëÇÑ ¿ëµµ°¡ °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ÀÌ ¶§¹®¿¡ ¾Ï ¹× Á¾¾ç ÇÁ·ÎÆÄÀϸµ(CTP) ±â¼ú ¼ö¿ä´Â ÇÏ·ù¿¡ ´ëÇÑ ¿ëµµ È®´ë¿Í ÇÔ²² À¯¸®ÇÑ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

Á¾¾ç ÇÁ·ÎÆÄÀϸµÀº ¾ÏÀ» °ËÃâÇϰí Á¾¾çÀÇ º´±â, ´ë»ç, ÇüÅÂÀÇ º¯È­¸¦ È®ÀÎÇϱâ À§ÇØ Ãß°¡·Î ¿¬±¸ÇÒ ¼ö ÀÖ´Â ÀáÀçÀûÀÎ ÀýÂ÷ÀÔ´Ï´Ù. À̰ÍÀº ÀÏ»óÀûÀÎ Áø´Ü°ú Ä¡·á ÀÇ»ç °áÁ¤¿¡ µµ¿òÀÌ µË´Ï´Ù. Á¾¾ç ÇÁ·ÎÆÄÀϸµÀº Áúº´ÀÇ ÁßÁõµµ ¹× °³ÀÎÀÇ À¯ÀüüÀÇ ÃàÀû¿¡ ±âÃÊÇÏ¿© ƯÁ¤ °³ÀÎÀ» ´ë»óÀ¸·Î ÇÏ´Â Ä¡·á¹ýÀ» °³¹ßÇϴµ¥ Áß¿äÇÑ Àǹ̸¦ °®½À´Ï´Ù.

NGS³ª in-situ hybridization°ú °°Àº °ËÃâ ¹× ½ÃÄö½Ì ±â¼úÀÇ °­È­´Â ¾Ï Á¾¾ç ÇÁ·ÎÆÄÀϸµ ÇÁ·Î¼¼½ºÀÇ ½Å¼ÓÈ­¿¡ µµ¿òÀÌ µÇ¾î ÇâÈÄ ¼ö³â°£ Å« °ßÀηÂÀ» ȹµæÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ÀÌ·¯ÇÑ ³ôÀº ä¿ë·üÀº ÃÖ¼ÒÇÑÀÇ ÀÚ¿ø°ú ´õ ³ôÀº Á¤È®µµ·Î °á°ú¸¦ ¾ò±â À§ÇÑ °¡¼ÓÈ­ ¼Óµµ·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù.

Á¾¾ç ÇÁ·ÎÆÄÀϸµ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • °³º°È­ ¾Ï ÀÇ·á´Â CTP ä¿ë¿¡¼­ °¡Àå À¯¸®ÇÑ ¿ëµµ ºÐ¾ß°¡ µÉ Àü¸ÁÀÔ´Ï´Ù.
  • ¾Ï¼¼Æ÷ÀÇ À¯Àüü, ¿¡ÇÇÀ¯Àüü, ¸ÞŸº¼·Ò ÇØ¼®À¸·ÎºÎÅÍ ¾ò¾îÁö´Â ±â´É Á¤º¸ÀÇ ¿ëµµÀÇ Â÷À̳ª »óÈ£ ÀÇÁ¸¼ºÀ¸·ÎºÎÅÍ, ÀÌ·¯ÇÑ ±â¼ú ºÎ¹®Àº ¼­·Î ¿¬µ¿ÇØ ¼ºÀå¸ç ¿¹Ãø ±â°£ Áß¿¡ À¯¸®ÇÑ ¼ºÀåÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀº ½ÅÈï °æÁ¦ ±¹°¡¿¡¼­ À¯·Â ±â¾÷ÀÇ Áַµµ°¡ ³ô¾ÆÁü¿¡ µû¶ó ÁÖ¿ä °æÁ¦ ±¹°¡¿¡¼­ÀÇ ´Ù¾çÇÑ °³¹ß·Î ÇâÈÄ 10³â°£ ´ëÆø ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý ¹× ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¾¾ç ÇÁ·ÎÆÄÀϸµ ½ÃÀåÀÇ º¯¼ö, µ¿Çâ ¹× ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ºñÁî´Ï½º ȯ°æ ºÐ¼®
    • ¾÷°è ºÐ¼®-Porter's Five Forces ºÐ¼®
    • PESTLE ºÐ¼®

Á¦4Àå Á¾¾ç ÇÁ·ÎÆÄÀϸµ ½ÃÀå : ±â¹ýº° ºñÁî´Ï½º ºÐ¼®

  • ±â¹ýº° ½ÃÀå Á¡À¯À²(2024³â, 2030³â)
  • ±â¹ýº° ºÎ¹® ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð, ¿¹Ãø ¹× µ¿Ç⠺м® : ±â¹ýº°(2018-2030³â)
  • À¯ÀüüÇÐ
  • ´Ü¹éÁúüÇÐ
  • ´ë»çüÇÐ
  • Èļº À¯ÀüÇÐ

Á¦5Àå Á¾¾ç ÇÁ·ÎÆÄÀϸµ ½ÃÀå : ±â¼úº° ºñÁî´Ï½º ºÐ¼®

  • ±â¼úº° ½ÃÀå Á¡À¯À²(2024³â, 2030³â)
  • ±â¼úº° ºÎ¹® ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð, ¿¹Ãø ¹× µ¿Ç⠺м® : ±â¼úº°(2018-2030³â)
  • ½ÃÄö½Ì ±â¼ú
  • ÀλçÀÌÃò ÇÏÀ̺긮µåÈ­
  • ¸é¿ªÁ¶Á÷È­ÇÐ
  • Á¤·® PCR
  • ¸¶ÀÌÅ©·Î¾î·¹ÀÌ

Á¦6Àå Á¾¾ç ÇÁ·ÎÆÄÀϸµ ½ÃÀå : ¿ëµµº° ºñÁî´Ï½º ºÐ¼®

  • ¿ëµµº° ½ÃÀå Á¡À¯À²(2024³â, 2030³â)
  • ¿ëµµº° ºÎ¹® ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð, ¿¹Ãø ¹× µ¿Ç⠺м® : ¿ëµµº°(2018-2030³â)
  • °³º°È­ ¾Ï ÀÇ·á
  • Á¾¾ç Áø´Ü
  • Á¶»ç

Á¦7Àå Á¾¾ç ÇÁ·ÎÆÄÀϸµ ½ÃÀå : Áö¿ªº° ÃßÁ¤ ¹× µ¿Ç⠺м®

  • Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®(2024³â, 2030³â)
  • Áö¿ªº° ½ÃÀå ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø ¹× µ¿Ç⠺м®(2018-2030³â)
  • ºÏ¹Ì
    • ±¹°¡º°(2018-2030³â)
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • ±¹°¡º°(2018-2030³â)
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ³ë¸£¿þÀÌ
    • µ§¸¶Å©
    • ½º¿þµ§
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ±¹°¡º°(2018-2030³â)
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ±¹°¡º°(2018-2030³â)
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ±¹°¡º°(2018-2030³â)
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • Äí¿þÀÌÆ®

Á¦8Àå °æÀï ±¸µµ

  • Âü°¡ ±â¾÷ °³¿ä
  • ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´× ºÐ¼®
  • ±â¾÷ ºÐ·ù
  • Àü·« ¸ÅÇÎ
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ ¹× ¸ñ·Ï
    • Illumina Inc.
    • Qiagen NV
    • Exact Sciences Corporation
    • NeoGenomics Laboratories
    • Oxford Gene Technology IP Limited
    • Bruker Spatial Biology, Inc.
    • GenomeDX
    • Guardant Health
    • Foundation Medicine, Inc.
AJY 25.05.12

Tumor Profiling Market Growth & Trends:

The global tumor profiling market size is expected to reach USD 21.7 billion by 2030, expanding at a CAGR of 10.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising research in the application of omics sciences in cancer detection is anticipated to influence market growth.

Technological advances in biotechnology have allowed for deeper insights into metabolism and gene expression. These have accelerated the application of advanced techniques such as metabolomics and epigenetics in cancer screening and detection. Thus, demand for cancer tumor/profiling (CTP) techniques is anticipated to witness lucrative growth with the expansion of downstream applications.

Cancer tumor profiling is a potential procedure through which cancer can be detected and studied further to identify the stage, metabolism, and changes in morphology of the tumor. This aids in routine diagnostics as well as therapeutic decision-making. Tumor profiling has significant importance in developing therapies aimed at a specific individual, based on the severity of ailment and genomic build up of the individual.

Enhanced detection and sequencing techniques such as NGS and in-situ hybridization can help speed up the cancer tumor profiling process and are estimated to gain much traction over the coming years. Their high adoption is attributive to accelerated speed in gaining results with minimum resources and greater accuracy.

Tumor Profiling Market Report Highlights:

  • Personalized cancer medicine is expected to be the most lucrative application segment for CTP adoption.
  • Owing to difference in usage of and interdependency of functional information from genomic, epigenomic, and metabolomic analysis of cancer cells, it can be expected that these technology segments will grow in tandem with each other and exhibit lucrative growth over the forecast years
  • Asia Pacific is projected to witness substantial growth over the next decade owing to various developments across major economies, with increased focus of dominant players in emerging economies as well

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Technique
    • 1.2.2. Technology
    • 1.2.3. Application
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Tumor Profiling Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Tumor Profiling Market: Technique Business Analysis

  • 4.1. Technique Market Share, 2024 & 2030
  • 4.2. Technique Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Technique, 2018 to 2030 (USD Million)
  • 4.4. Genomics
    • 4.4.1. Genomics Market, 2018 - 2030 (USD Million)
  • 4.5. Proteomics
    • 4.5.1. Proteomics Market, 2018 - 2030 (USD Million)
  • 4.6. Metabolomics
    • 4.6.1. Metabolomics Market, 2018 - 2030 (USD Million)
  • 4.7. Epigenetics
    • 4.7.1. Epigenetics Market, 2018 - 2030 (USD Million)

Chapter 5. Tumor Profiling Market: Technology Business Analysis

  • 5.1. Technology Market Share, 2024 & 2030
  • 5.2. Technology Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Technology, 2018 to 2030 (USD Million)
  • 5.4. Sequencing Techniques
    • 5.4.1. Sequencing Techniques Market, 2018 - 2030 (USD Million)
  • 5.5. In Situ Hybridization
    • 5.5.1. In Situ Hybridization Market, 2018 - 2030 (USD Million)
  • 5.6. Immunohistochemistry
    • 5.6.1. Immunohistochemistry Market, 2018 - 2030 (USD Million)
  • 5.7. qPCR
    • 5.7.1. qPCR Market, 2018 - 2030 (USD Million)
  • 5.8. Microarray
    • 5.8.1. Microarray Market, 2018 - 2030 (USD Million)

Chapter 6. Tumor Profiling Market: Application Business Analysis

  • 6.1. Application Market Share, 2024 & 2030
  • 6.2. Application Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 6.4. Personalized Cancer Medicine
    • 6.4.1. Personalized Cancer Medicine Market, 2018 - 2030 (USD Million)
  • 6.5. Oncological Diagnostics
    • 6.5.1. Oncological Diagnostics Market, 2018 - 2030 (USD Million)
  • 6.6. Research
    • 6.6.1. Research Market, 2018 - 2030 (USD Million)

Chapter 7. Tumor Profiling Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Tumor Profiling Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Tumor Profiling Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Tumor Profiling Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Tumor Profiling Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Tumor Profiling Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Tumor Profiling Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Tumor Profiling Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Tumor Profiling Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Tumor Profiling Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Tumor Profiling Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Norway
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Norway Tumor Profiling Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Denmark Tumor Profiling Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Sweden
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Sweden Tumor Profiling Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Tumor Profiling Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Tumor Profiling Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Tumor Profiling Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Tumor Profiling Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Tumor Profiling Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Tumor Profiling Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Tumor Profiling Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Tumor Profiling Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Tumor Profiling Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Tumor Profiling Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Tumor Profiling Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Tumor Profiling Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Tumor Profiling Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Tumor Profiling Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Tumor Profiling Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Illumina Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Qiagen N.V.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Exact Sciences Corporation
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. NeoGenomics Laboratories
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Oxford Gene Technology IP Limited
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Bruker Spatial Biology, Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. GenomeDX
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Guardant Health
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Foundation Medicine, Inc.
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦